The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
Open accessAbstract
Pleomorphic xanthoastrocytoma (PXA) is low-grade glial neoplasm principally affecting children and young adults. Approximately 40% of PXA are reported to recur within 10 years of primary resection. Upon recurrence, patients receive radiation therapy and conventional chemotherapeutics designed for high-grade gliomas. Genetic changes that can be targeted by selective therapeutics have not been extensively evaluated in PXA and ancillary diagnostic tests to help discriminate PXA from other pleomorphic and often more aggressive astrocytic malignancies are limited. In this study, we apply the SNaPshot multiplexed targeted sequencing platform in the analysis of brain tumors to interrogate 60 genetic loci that are frequently mutated in 15 cancer genes. In our analysis we detect BRAF V600E mutations in 12 of 20 (60%) WHO grade II PXA, in 1 of 6 (17%) PXA with anaplasia and in 1 glioblastoma arising in a PXA. Phospho-ERK was detected in all tumors independent of the BRAF mutation status. BRAF duplication was not detected in any of the PXA cases. BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Notably, we now identify the BRAF V600E mutation in approximately 60% of grade II PXA, a similar mutation rate as seen in malignant melanoma [43].”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“In total, BRAF V600E mutation in standard glioblastomas has been reported in approximately 1.7% of cases (5 of nearly 300 cases) [25–29].”
BackgroundInfluentialIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
McDonald-McGinn, D. M., Sullivan, K. E., Marino, B., Philip, N., Swillen, A., Vorstman, J. A. S., Zackai, E. H., Emanuel, B. S., Vermeesch, J. R., Morrow, B. E., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.71 · Cited by 2,236
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Self-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Surgical Pathology of the Nervous System and its Coverings
Blumbergs, P. C. (2003) · Pathology · doi:10.1016/s0031-3025(16)39703-3 · Cited by 918
Diagnostic histopathology of tumors
Fletcher., E. B. C. D. M. (2013) · Elsevier eBooks · Cited by 672
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33656 · Cited by 523
Kepes, J. J., Rubinstein, L. J., & Eng, L. F. (1979) · Cancer · doi:10.1002/1097-0142(197911)44:5<1839::aid-cncr2820440543>3.0.co;2-0 · Cited by 481
Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 449
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Self-citationDias‐Santagata, D., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 396
Self-citationPleomorphic xanthoastrocytoma: What do we really know about it?
Giannini, C., Scheithauer, B. W., Burger, P. C., Brat, D. J., Wollan, P. C., Lach, B., & O'Neill, B. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9<2033::aid-cncr22>3.0.co;2-z · Cited by 335
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq007 · Cited by 324
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009) · Oncogene · doi:10.1038/onc.2009.73 · Cited by 321
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Forshew, T., Tatevossian, R. G., Lawson, A. R., Ma, J., Neale, G., Ogunkolade, B. W., Jones, T. A., Aarum, J., Dalton, J., Bailey, S., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2558 · Cited by 304
Sievert, A. J., Jackson, E. M., Gai, X., Hakonarson, H., Judkins, A. R., Resnick, A. C., Sutton, L. N., Storm, P. B., Shaikh, T. H., & Biegel, J. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00225.x · Cited by 255
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M.-Y. C., Yu, M., Fisher, P. G., Rowitch, D. H., Ford, J. M., Berger, M. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1851 · Cited by 251
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Molecular Classification of Low-Grade Diffuse Gliomas
Kim, Y.-H., Nobusawa, S., Mittelbronn, M., Paulus, W., Brokinkel, B., Keyvani, K., Sure, U., Wrede, K., Nakazato, Y., Tanaka, Y., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100680 · Cited by 240
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
Von Deimling, A., Korshunov, A., & Hartmann, C. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00454.x · Cited by 174
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas
Knobbe-Thomsen, C. B., REIFENBERGER, J., & Reifenberger, G. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0929-9 · Cited by 156
Perry, A., Giannini, C., Scheithauer, B. W., Rojiani, A. M., Yachnis, A. T., Seo, &. S., Johnson, P. C., Kho, J., & Shapiro, S. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199707000-00004 · Cited by 136
Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis
Camelo-Piragua, S. I., Jansen, M., Ganguly, A., Kim, J. C., Louis, D. N., & Nutt, C. L. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0632-y · Cited by 119
Self-citationGone FISHing: Clinical Lessons Learned in Brain Tumor Molecular Diagnostics over the Last Decade
Horbinski, C., Miller, C. R., & Perry, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00453.x · Cited by 118
Weber, R. G., Hoischen, A., Ehrler, M., Zipper, P., Kaulich, K., Blaschke, B., Becker, A. J., Weber‐Mangal, S., Jauch, A. T., Radlwimmer, B., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209851 · Cited by 118
Molecular genetic analysis of giant cell glioblastomas.
Meyer‐Puttlitz, B., Hayashi, Y., Waha, A., Rollbrocker, B., Boström, J. P., Wiestler, O. D., Louis, D. N., Reifenberger, G., & von Deimling, A. (1997) · Europe PMC (PubMed Central) · Cited by 103
Self-citationPahapill, P. A., Ramsay, D. A., & Maestro, R. F. D. (1996) · Neurosurgery · doi:10.1097/00006123-199604000-00038 · Cited by 103
Lurkin, I., Stoehr, R., Hurst, C. D., van Tilborg, A. A. G., Knowles, M. A., Hartmann, A., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008802 · Cited by 102
Mutation analysis of B-RAF gene in human gliomas
Basto, D., Trovisco, V., Lopes, J. M., Martins, A. M., Pardal, F., Soares, P., & Reis, R. M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0936-x · Cited by 90
Classification and Grading of Low‐Grade Astrocytic Tumors in Children
Giannini, C., & Scheithauer, B. W. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb01064.x · Cited by 69
Diagnostic pathology of nervous system tumours
Ironside, J. W. (2002) · Churchill Livingstone eBooks · Cited by 68
Molecular genetic alterations in pleomorphic xanthoastrocytoma
Paulus, W., Lisle, D. K., Tonn, J. C., Wolf, H. K., Roggendorf, W., Reeves, S. A., & Louis, D. N. (1996) · Acta Neuropathologica · doi:10.1007/s004010050428 · Cited by 66
Self-citationp53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas
Peraud, A., Watanabe, K., Plate, K. H., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199711000-00008 · Cited by 65
Kaulich, K., Blaschke, B., Nümann, A., von Deimling, A., Wiestler, O. D., Weber, R. G., & Reifenberger, G. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.12.1092 · Cited by 63
Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma
Giannini, C., Hebrink, D. M., Scheithauer, B. W., Tos, A. P. D., & James, C. D. (2001) · Neurogenetics · doi:10.1007/s100480100116 · Cited by 60
Diagnostic Pathology of Nervous System Tumours
Buckland, M. E. (2003) · Pathology · doi:10.1016/s0031-3025(16)34347-1 · Cited by 52
Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma
Flaherty, K. T. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-9-201011020-00008 · Cited by 40
Pleomorphic xanthoastrocytoma as a component of a temporal lobe cystic ganglioglioma: a case report
Sugita, Y., Irie, K., Ohshima, K., Hitotsumatsu, T., Satō, O., & Arimura, K. (2009) · Brain Tumor Pathology · doi:10.1007/s10014-009-0244-1 · Cited by 30
RAF expression in human astrocytic tumors
Hagemann (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000097 · Cited by 30
Murray, J. C., Donahue, D. J., Malik, S. I., Dzurik, Y., Braly, E. Z., Dougherty, M. J., Eaton, K. W., & Biegel, J. A. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0350-2 · Cited by 21
Cited by
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Self-citationExome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Brastianos, P. K., Taylor-Weiner, A., Manley, P. E., Jones, R. T., Dias-Santagata, D., Thorner, A. R., Lawrence, M. S., Rodriguez, F. J., Bernardo, L. A., Schubert, L., et al. (2014) · Nature Genetics · doi:10.1038/ng.2868 · Cited by 521
Self-citation
Metadata
- Authors
- Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., Louis, D. N., & Santagata, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-03-29
- Volume
- 6
- Issue
- 3
- Pages
- e17948
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2010760434
- Cited by
- 315
- References
- 47
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.